Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Del Priore

Internal Medicine Chicago, IL Medical Doctor

NPI 1275888216 CMS profile 1391962

2600 S Michigan Ave Ste 305, Chicago, IL 60616

Open in the dashboard

General payments

$8,814

409 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,428 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Anthony Del Priore of Chicago, IL is reported in the CMS Open Payments database as having received $8,814 across 409 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,428 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,829 74
2024 General $1,794 76
2023 General $1,391 58
2022 General $1,431 65
2021 General $589 30
2020 General $1,077 62
2019 General $702 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Del Priore
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anthony Del Priore were reported at $1,829. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anthony Del Priore Internal Medicine median Middle half National median
2019 $702 $159 $48–$570 $163
2020 $1,077 $119 $33–$402 $114
2021 $589 $135 $37–$521 $132
2022 $1,431 $141 $42–$496 $149
2023 $1,391 $149 $45–$519 $160
2024 $1,794 $154 $47–$537 $164
2025 $1,829 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,680 70 payments
  2. Novo Nordisk Inc $1,060 67 payments
  3. Lilly USA, LLC $1,011 52 payments
  4. Pfizer Inc. $530 23 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $513 20 payments
  6. Novartis Pharmaceuticals Corporation $480 24 payments
  7. Abbott Laboratories $429 17 payments
  8. Amgen Inc. $356 18 payments
  9. AbbVie, Inc. $232 12 payments
  10. Exact Sciences Corporation $214 9 payments
  11. Other $2,309 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,784 406 payments
  2. Education $29 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $894 39 payments
  2. Ozempic $645 43 payments
  3. MOUNJARO $520 24 payments
  4. RYBELSUS $477 30 payments
  5. Kerendia $424 17 payments
  6. TRULICITY $384 20 payments
  7. FreeStyle Libre 3 $337 12 payments
  8. ELIQUIS $336 15 payments
  9. AIRSUPRA $311 10 payments
  10. JARDIANCE $283 15 payments
  11. Other $6,798 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 217 drugs

Part D claims

17,843

Median for Family Practice: 1,826

Drug cost

$1,374,960

Median for Family Practice: $120,094

Branded share of claims

21.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 815 $302,305
Ozempic Semaglutide Brand 81 $109,466
Xarelto Rivaroxaban Brand 226 $81,355
Farxiga Dapagliflozin Propanediol Brand 99 $65,787
Mounjaro Tirzepatide Brand 30 $44,559
Jardiance Empagliflozin Brand 98 $44,309
Entresto Sacubitril/Valsartan Brand 72 $43,086
Trulicity Dulaglutide Brand 33 $38,477
Januvia Sitagliptin Phosphate Brand 54 $32,606
Kerendia Finerenone Brand 25 $32,447

The 10 drugs with the highest cost, of 217 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$264,677

Of which drugs: $1,726

Medicare patients

452

Average age 75

Services billed

6,378

265 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 49%
Heart failure 41%
Ischemic heart disease 41%
Chronic kidney disease 40%
Depression 34%
Alzheimer's or dementia 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,184

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $362
$362 99 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $152
$152 25 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $146
$146 — —
MOUNJARO
  • Lilly USA, LLC $114
$114 30 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $97
$97 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

409 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record